4D Molecular Therapeutics, Inc.
Every calculator, already run for FDMT
Open the full toolkit →You have the numbers on FDMT. Get the argument.
A written report on which of these readings actually decide the outcome for 4D Molecular Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering FDMTAnalyst Price Target Disagreement for 4D Molecular Therapeutics, Inc.
Wall Street's bull case implies +217% from the current price; the bear case implies +46%. A 171% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geograph…
FDMT — frequently asked
Is FDMT a buy right now?
Wall Street's consensus rating on 4D Molecular Therapeutics, Inc. is Strong Buy across 12 analysts, with a mean price target of $29.10 (+149% vs. the current $11.68). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is FDMT's next earnings date?
4D Molecular Therapeutics, Inc. is next scheduled to report earnings around Aug 12, 2026. A full FDMT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for 4D Molecular Therapeutics, Inc.?
Analysts covering 4D Molecular Therapeutics, Inc. (FDMT) range from a bear-case target of $17.00 to a bull-case high of $37.00, with a mean consensus target of $29.10 across 10 analysts. The spread of $20.00 (171% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare 4D Molecular Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For 4D Molecular Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full FDMT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on 4D Molecular Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.